Descriptive Study of the Initial Management of Young Children With Moderate Acute BRONCHiotitis With Home Hospitalisation (BRONCHAD)

April 20, 2026 updated by: Elsan

The occurrence of a first episode of acute bronchiolitis in an infant or young child (3 months-2 years) always represents a medical event that generates stress for parents and in some cases for the primary care physician when it is necessary to decide on the child's orientation for treatment. Each year, during the winter season, this pathology affects 30% of infants under two years old (480,000 annual cases in France), generates approximately 30,000 hospitalizations and exposes to an overall mortality risk of 0.08%.

According to the recommendations of the HAS (2019), moderate bronchiolitis does not require systematic hospitalization and can be managed in a Home Hospitalization (HAD) context.

When the child's examination data do not find signs of severity, the SpO2 measurement is greater than 92% and the family context allows for return home, HAD management is a reasonable option and represents an alternative to the classic scheme of assessing the level of severity by the emergency department and subsequent hospitalization if necessary. HAD management is carried out within the framework of a very structured "patient pathway", codified and supervised by the pediatric teams and doctors of this department. This patient pathway concerns children with a moderate form of bronchiolitis without oxygen requirements at the time of inclusion. This must be 48 hours from the onset of the child's respiratory clinical signs.

The main objective of this study is to describe the need for oxygen therapy for a young child with moderate acute bronchiolitis syndrome during home hospitalization (HAD) care.

Study Overview

Status

Recruiting

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Poitiers, France, 86000
        • Recruiting
        • Polyclinique de Poitiers - HAD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Babies between 2 months and 2 years old

Description

Inclusion Criteria:

  • Any infant with moderate bronchiolitis according to the HAS definition (except for the SpO2 criterion which must be greater than or equal to 92% to avoid the patient being on oxygen therapy upon admission)
  • Age > 2 months and ≤ 2 years
  • Respiratory syndrome for 48 hours
  • Infant with a first episode of bronchiolitis
  • Referral of the general practitioner/treating pediatrician for home hospitalisation care
  • Parents' agreement for the choice of home hospitalisation care
  • Non-opposition or free and informed consent of both parents to the use of the child's health data

Exclusion Criteria:

  • Patient not receiving health protection
  • Comorbidities: congenital heart disease with shunt, chronic pulmonary pathology including bronchopulmonary dysplasia, neuromuscular pathology, immune deficiency, multiple disabilities Congenital heart disease
  • Refusal of one or both parents for the proposed pathway
  • Doubts about the parents' understanding of the nature of home hospitalisation care
  • Severe bronchiolitis or with saturation < 92%

    • Moderate bronchiolitis but evolving for less than 48 hours
    • Cases of psychiatric pathologies or depressive syndrome diagnosed in the parents.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oxygenotherapy
Time Frame: one month
Need for oxygen therapy during home hospitalisation care
one month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oxygen therapy assistance
Time Frame: up to one month
Oxygen therapy assistance during home hospitalization care
up to one month
Home hospitalization support
Time Frame: up to one month
Duration of home hospitalization support
up to one month
Hospitalization time
Time Frame: up to one month
hospitalization during home hospitalization care
up to one month
QUALIN questionnaire
Time Frame: day 1, day 7 and one month
QUALIN questionnaire is a 34-item scale to assess an infant's quality of life.
day 1, day 7 and one month
Hospital Anxiety and Depression Scale questionnaire
Time Frame: day 1, day 7 and one month
HADS questionnaire has 14 items between 0 and more than 11 points
day 1, day 7 and one month
Direct costs
Time Frame: day 1, day 7 and one month
daily cost of home hospitalization without oxygen, daily cost of home hospitalization with oxygen, GHS bronchiolitis level 2
day 1, day 7 and one month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 14, 2025

Primary Completion (Estimated)

February 14, 2027

Study Completion (Estimated)

March 14, 2027

Study Registration Dates

First Submitted

February 7, 2025

First Submitted That Met QC Criteria

February 21, 2025

First Posted (Actual)

February 24, 2025

Study Record Updates

Last Update Posted (Actual)

April 21, 2026

Last Update Submitted That Met QC Criteria

April 20, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bronchiolitis

Subscribe